Q-omics provides the consensus-scored PCDH7 profile across patient tissues and cancer cell-line models. PCDH7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PCDH7 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PCDH7 protein abundance shows 23,145 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where PCDH7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH7 survival associations across molecular data types. PCDH7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH7 RNA expression–survival associations across cancer types. High PCDH7 expression shows unfavorable associations in KIRP, MESO, LUAD and STAD, but favorable associations in LGG and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PCDH7 RNA expression.
This table summarizes PCDH7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PCDH7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH7 shows lower tumor expression in KIRC, KICH, BLCA and COAD and higher tumor expression in HNSC and LUAD. The KIRC box plot shows higher PCDH7 RNA expression in normal versus tumor tissue (log2 FC = −1.240, t-test p < 0.001).
This table shows molecular features associated with PCDH7 in patient tissues and cancer cell lines. In patient samples, PCDH7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDH7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
